🌍What began as a CholangioConnect mentor-mentee match in 2022 has become a friendship spanning continents. Living thousands of miles apart in Kenya and New York, Irungu and his mentor Erica supported one another through life’s challenges. Over the years, they stayed connected through video calls, texts, family photos, and shared milestones. After several missed opportunities to meet, they finally connected in person while Irungu was in New York City for the Tribeca Film Festival, where the film he performs in was selected for screening. From brunch near Grand Central to a walk through Bryant Park, their conversation flowed as naturally as it had for years. Their story is a reminder that the connections formed through this community can grow beyond mentorship into lasting friendship. Mentorship is available for patients, caregivers, and bereaved caregivers. Please learn more and request a mentor or volunteer to be one here: curecca.org/get-one-on-one-s…

Thanks to @curecc @CharityAMMF and @atuvibi for joining us in 📍Rhodes for the @enscca and @PrecisionBTCnet Annual meeting 💚💜💚 Did you know that ClarIDHy (ivosidenib registration trial) design was impacted by the @curecc input? That is how strong patient advocacy can be…

@atuvibi in 📍Rhodes for the @enscca and @PrecisionBTCnet Annual meeting 💚Plans to visit European Parliament 💚Project on socioeconomic analisis in BTC 👉All following steps of who were here first (🔝guide) - @CharityAMMF @curecc #CONFIA

📢 Save the Date! The 8th Annual Cholangiocarcinoma Summit is coming to Grapevine, Texas, October 15–16, 2026. This is an opportunity to share data from your research studies on cholangiocarcinoma (CCA) or other biliary tract cancers with your colleagues. Please see below for the specific categories and the instructions for submitting a poster abstract for presentation during the meeting. 🗓️ Submit a Poster Abstract by Friday, August 7, 2026. 🔗 ccanewsonline.com/summit/pos…

Are you balancing work & cancer? Get tips, tools & more at the @CancerAndCareer virtual National Conference on Work & Cancer. Register today! cancerandcareers.org/confere… #CACconf

Join our upcoming Webinar: A trial of next-generation immunotherapy (Rilvegostomig) plus chemotherapy in advanced biliary tract cancer (ARTEMIDE-Biliary02) on June 16, 2026, at 4:00 p.m. ET with Dr. Lipika Goyal. Patients with newly diagnosed advanced biliary tract cancer are often treated with immunotherapy plus chemotherapy. This webinar will discuss a new ongoing clinical trial in biliary tract cancer investigating a new immunotherapy drug called rilvegostomig in combination with standard chemotherapy. The study called ARTEMIDE-Biliary02 is a phase III randomized global study of rilvegostomig or durvalumab in combination with chemotherapy in first-line treatment of advanced biliary tract cancer.  This webinar is sponsored by AstraZeneca. Register today at curecca.link/june16th.

The 2026 Los Angeles Cholangiocarcinoma Symposium is set to convene in Los Angeles, drawing together leading experts, researchers, healthcare professionals, patients, and advocates. This event promises to be a crucial platform for sharing the latest advancements and addressing the challenges in cholangiocarcinoma research and treatment. 🗓️ September 19, 2026 ⏱️ 8:00am – 4:00pm 📍University of Southern California Snacks, Beverages, and Lunch will be served Register today at curecca.link/la2026.

Patients often receive biomarker test results without fully understanding what they mean. This free webinar will help explain common testing terms, reports, and an AI tool to understand results.    📅 June 15  🔗 Register here: shorturl.at/0PGJU    #BiomarkerTesting #PrecisionMedicine #CancerCare

🌟 Today, on National Cancer Survivors Day, we celebrate the incredible strength and resilience of cholangiocarcinoma patients and survivors. Your journey is a testament to the power of community and the hope that research brings. With every step forward, we embrace our motto, "Strength in Community, Hope in Research." Together, we support one another, fuel advancements, and foster a future where hope shines brighter than ever. Thank you for your courage and determination. You inspire us all. 💪🏼💚

Exciting to see our manuscript out @JournalofExper1 B7-H3 CAR T cells eradicate intrahepatic cholangiocarcinoma and induce durable response in preclinical models. @MGHSurgery @CedarsSinaiMed @curecc link.springer.com/article/10…

🆕@JCOPO_ASCO 💡Such a beautiful story of real world🌎 precision medicine. Meet➡️#ERRFI1🎯 📝Time to add➕this to ACTIONABLE Biomarkers🔐for #cholanagiocarcinoma @curecc. @NCCN 👇🏽Patient in paper, I took off hospice to give Erlotinib💊. @OncoAlert 🔗ascopubs.org/doi/10.1200/PO-…

CCF’s new CholangioPath app empowers patients to connect with a Patient Advocate, explore treatment information, receive reminders about educational events, and access new resources, making it easier to stay informed and supported throughout your journey. Learn more and download the CholangioPAth app today at curecca.org/app. Thank you to our founding sponsors, Jazz Pharmaceuticals, Taiho Oncology, Incyte, and Compass Therapeutics for making this resource possible.

Publication Alert ‼️ Delighted to share this collaborative work. I am deeply grateful to my mentors and co-authors for their invaluable guidance, support, and contributions. @JavleMilind @Fen_Saj @pashtoonkasi @UTMDAnderson @DrShubhamPant @MiteshBorad @JCO_ASCO @JCOPO_ASCO @ASCO @OncLive @oncodaily @GiOncNow @curecc Thank you so much @JavleMilind for this opportunity 🙏 👉 ascopubs.org/doi/full/10.120…

ascopubs.org/doi/full/10.120… Some stories are so meaningful @https://www.cholangio.ca/cycle/cynthia. Drug availability in oncology is a major limitation. @mcuban and his @costplusdrugs made it possible for many to get access to this EGFR inhibitor @curecc @MiteshBorad

📢 Save the Date! The 8th Annual Cholangiocarcinoma Summit is coming to Grapevine, Texas, October 15–16, 2026. Researchers and clinicians are invited to share their work by submitting a poster abstract for this year’s Summit. This is an opportunity to showcase the latest advances in cholangiocarcinoma research and connect with leaders across the field. 🗓️ Submit a Poster Abstract by Friday, August 7, 2026. 🔗 ccanewsonline.com/summit/pos…

Thank you to @curecc's Dir. of Research @amandanottke for this excellent overview on what the @US_FDA approval of #zenocutuzumab means for patients with #cholangiocarcinoma.

@ASCO Abstract 3008: #DrlingjunZhu presented data on targeting KRAS G12D in CCA with GFH375: N=20; 75% in 3L , ORR 40%, Med PFS 6.2 mo, OS not reached. Direction of future research in CCA @curecc @CharityAMMF @MCRCnews GI toxicities, cytopenias AEs.

@GIcancerDoc presents phase 3 #FIGHT-302 study of #pemigatinib in patients with #CCA with #FGFR2 gene fusion at #ASCO26 @ASCO @JCO_ASCO @curecc @CharityAMMF @atuvibi @VoiesBiliaires #APIC @CcaEns @PrecisionBTCnet

National Cancer Survivors Month Grateful to be in the company of these survivors(friends) Steven West – Dx 2015
Lisa Craine – Dx 2010
Patrick Corrigan – Dx 2006
Melinda Bachini – Dx 2009
Matt Reidy – Dx 2013 Thank you @curecc for your advocacy and for building a community

Twenty years ago, a cholangiocarcinoma diagnosis often came with more questions than answers. There were few treatment options, little public awareness, limited research funding, and no patient community. Patients and families often faced this disease feeling isolated and without hope. While many patients still face uncertainty today, there is now more hope, knowledge, and progress than ever before. Today, the landscape looks different because of relentless research, advocacy, and the support of people like you. With your support today, we can help drive breakthroughs by advancing research, expanding advocacy, and ensuring every cholangiocarcinoma diagnosis is met with hope, information, and care. Make a gift today to help continue this momentum at curecca.link/c4c26.